Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αDC1 vaccine + CKM
- Development stage
- Discontinued
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules, RNA Therapeutics → Nucleic Acid Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranodal, Intradermal, Oral, Intravenous
01
Overview
The αDC1 (alpha-DC1) vaccine is an autologous, tumor antigen-loaded dendritic cell immunotherapy developed by Dr. David L. Bartlett and colleagues. This biologic therapy consists of patient-derived dendritic cells that are matured into an alpha-type-1 phenotype and loaded with antigens from the patient's own peritoneal tumors. The vaccine is administered via intranodal and intradermal injections in combination with a chemokine modulatory regimen (CKM) consisting of celecoxib, interferon-alpha-2b, and rintatolimod. The CKM regimen is designed to reprogram the tumor microenvironment to enhance the recruitment and activation of CD8+ T-cells. This combination was evaluated as an adjuvant therapy following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies, including appendiceal cancer and colorectal cancer with peritoneal metastases. However, clinical trials were terminated due to challenges in obtaining sufficient tumor cells and failure to meet efficacy thresholds.
- Other names
- Autologous tumor antigen-loaded dendritic cell vaccineαDC1 vaccinealpha-DC1 vaccinealpha-DC-1 vaccinealpha-DC 1 vaccine
02
Targets
IFNAR1 (Interferon alpha/beta receptor 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on αDC1 vaccine + CKM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αDC1 vaccine + CKM.